Foresight Diagnostics and Roche Sign Licensing Deal for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma

Licensing Agreement with Roche

• Resolution of Litigation: Foresight Diagnostics has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems, effectively closing ongoing litigation. All claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.
• Terms of the Agreement: Foresight has granted Roche a limited royalty-bearing non-exclusive sublicense for the use of its PhasED-Seq™ technology specifically for developing in vitro diagnostic (IVD) kits for Non-Hodgkin's Lymphoma (NHL).

Intellectual Property Rights

• Ownership of Technology: The intellectual property rights for the PhasED-Seq technology remain with Stanford University, while Foresight retains an exclusive license for all uses and geographies.

Company Mission and Technology

• Focus on Cancer Diagnostics: Jake Chabon, CEO of Foresight Diagnostics, expressed satisfaction with the resolution, emphasizing the company's commitment to advancing diagnostics that improve cancer patient outcomes.
• Foresight CLARITY™ Platform: Foresight Diagnostics operates a CLIA-registered laboratory and offers a liquid biopsy platform, Foresight CLARITY™, which measures minimal residual disease (MRD) with detection limits in parts per million. This technology aims to provide actionable insights for personalized treatment in cancer care.
• PhasED-Seq™ Technology: The PhasED-Seq™ technology enhances mutation detection accuracy by requiring the detection of two separate non-reference events in a single DNA molecule, allowing for ctDNA detection at levels below one part-per-million (<0.0001%). This method has been validated through extensive testing on thousands of patient samples.